Aurinia Pharmaceuticals Inc. reported total revenue of $83.7 million for the three months ended September 30, 2026, marking a 14% increase compared to the same period in 2025. Over the first nine months of 2026, total revenue reached $244.6 million, representing a 19% increase from $205.9 million in the prior year.
Net product sales of LUPKYNIS, the company's oral therapy for lupus nephritis, totaled $79.4 million for the third quarter and $232.4 million for the nine-month period, rising 12% and 18%, respectively, from 2025 figures. Additionally, license, collaboration, and royalty revenue increased to $4.3 million for the quarter and $12.2 million for the year-to-date period, up 54% and 39% year-over-year.
On the income statement, the company reported net income of $31.7 million for the third quarter and $103.5 million for the nine months ended September 30, 2026. Diluted earnings per share were $0.23 for the quarter and $0.76 for the nine months, compared to $0.23 and $0.55 in the prior year.
Aurinia updated its financial guidance for 2026, increasing total revenue guidance from a range of $315 million to $325 million to a new range of $325 million to $330 million. The company also narrowed its net product sales guidance for 2026 from a range of $305 million to $315 million to a range of $310 million to $315 million.
As of September 30, 2026, Aurinia held cash, cash equivalents, restricted cash, and investments totaling $486.9 million, an increase from $398.0 million at December 31, 2025. During the nine months ended September 30, 2026, cash outflows from financing activities were $53.2 million, primarily driven by the repurchase of 5.0 million common shares for $74.9 million, partially offset by proceeds from the issuance of common shares for equity awards.
In terms of clinical progress, Aurinia has initiated the PRESERVE Phase 4 study, a multicenter trial investigating the combination of LUPKYNIS with belimumab, obinutuzumab, or anifrolumab in lupus nephritis patients. The study aims to evaluate whether a multi-target approach improves outcomes, with a planned enrollment of approximately 150 patients across 50 sites in the U.S. Additionally, the company has initiated clinical development of aritinercept, a dual inhibitor of B cell-activating factor (BAFF) and APRIL, across four potential indications.
